Replies to post #235151 on Biotech Values

[DewDiligence]

Pro-ENTA—(facetious)—tweet re ALGS IPO:

So, $ENTA has $400+ million of net balance sheet cash, generates $200 mill/yr of royalty (i.e., cost free) revenue, and has a broader wholly owned pipeline with a proven history of bringing 2 blockbuster drugs to market, but has a market cap of $900 million. Makes total sense...

— Florida Hedgie (@FLHedgie) October 16, 2020

[DewDiligence]

ALGS starts phase-1 of ALG-000184 in HBV:

https://www.globenewswire.com/news-release/2020/10/30/2117727/0/en/Aligos-Therapeutics-Doses-First-Subject-in-Phase-1-Proof-of-Concept-Study-of-Small-Molecule-Drug-Candidate-ALG-000184-for-Chronic-Hepatitis-B.html

ALG-000184 is a CpAM, the same drug class as ENTA’s EDP-514 (#msg-156787041).

[DewDiligence]

ALGS +11% on MRK collaboration_in_NASH—upfront_amount_not disclosed:

https://finance.yahoo.com/news/aligos-enters-exclusive-license-research-130000438.html